Yu Yi-Jun, Liu Ya-Dong, Xu Xin, Ma Xiao-Wang
Department of General Surgery, Hangzhou Second People's Hospital, Hangzhou 310015, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2009 Jan;12(1):48-51.
To inquire into the diagnostic significance of cytokeratin 19(CK19) and cytokeratin 20(CK20) expression on hematogenous micrometastasis of colorectal cancer.
Forty-four patients with colorectal cancer were collected as colorectal cancer groups, and another 18 patients treated with abdominal surgical operations because of benign diseases were collected as benign disease group. Blood of all the patients was harvested from their portal and peripheral veins, and CK19 and CK20 levels in the blood were determined by RT-PCR.
There were no positive expression of CK19 and CK20 in the portal and peripheral blood of all the patients in benign disease group. Of the colorectal cancer group, 34 patients(77.3%) appeared positive expressions of CK19 and/or CK20 in portal and peripheral blood, and there was significant difference in the expressions of CK19 and CK20 between the two groups(P<0.05). Within the colorectal cancer group, the positive expression rates of CK19 and CK20 in peripheral blood were 36.4% and 52.3%, and the rates in portal blood were 59.1% and 72.7%. The rates of portal blood were significantly higher than those of peripheral blood(P<0.05). The positive expression rate in patients at stage III( was significantly higher than that in patients at stage I( orII( (P<0.05). The postoperative metastasis and recurrence rate of colorectal cancer in patients with positive expression of CK19 and CK20 in peripheral blood was 61.5%, which was significantly higher than that(25.0%) in patients with positive expression in portal blood only(P<0.05).
In patients with colorectal cancer, the expressions of CK19 and CK20, which are determined by RT-PCR in blood from portal and peripheral veins, are the sensitive and specific indexes for diagnosing hematogenous micrometastasis of the cancer.
探讨细胞角蛋白19(CK19)和细胞角蛋白20(CK20)表达对结直肠癌血行微转移的诊断意义。
收集44例结直肠癌患者作为结直肠癌组,另收集18例因良性疾病行腹部手术治疗的患者作为良性疾病组。采集所有患者门静脉血和外周静脉血,采用逆转录-聚合酶链反应(RT-PCR)检测血液中CK19和CK20水平。
良性疾病组所有患者门静脉血和外周血中CK19和CK20均无阳性表达。结直肠癌组中,34例患者(77.3%)门静脉血和外周血中出现CK19和/或CK20阳性表达,两组间CK19和CK20表达差异有统计学意义(P<0.05)。结直肠癌组内,外周血中CK19和CK20阳性表达率分别为36.4%和52.3%,门静脉血中分别为59.1%和72.7%。门静脉血中的表达率显著高于外周血(P<0.05)。Ⅲ期患者阳性表达率显著高于Ⅰ期或Ⅱ期患者(P<0.05)。外周血中CK19和CK20阳性表达的结直肠癌患者术后转移复发率为61.5%,显著高于仅门静脉血阳性表达患者的转移复发率(25.0%)(P<0.05)。
对于结直肠癌患者,通过RT-PCR检测门静脉血和外周静脉血中CK19和CK20的表达,是诊断该癌血行微转移的敏感且特异的指标。